electroCore, Inc.
Change company Symbol lookup
Select an option...
ECOR electroCore, Inc.
DPZ Domino's Pizza Inc
KEY KeyCorp
AMH-F American Homes 4 Rent
LYB LyondellBasell Industries NV
CHD Church & Dwight Co Inc
ATHX Athersys Inc
PARR Par Pacific Holdings Inc
EVER EverQuote Inc
MRNA Moderna Inc
Go

Company profile

ElectroCore, Inc., formerly ElectroCore LLC, is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy, which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep and pain disorders.

Postmarket

Last Trade
Delayed
$1.88
0.005 (0.27%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.88
Day's Change
0.145 (8.38%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.89
Day's Low
1.71
Volume
(Heavy Day)
Volume:
856,908

10-day average volume:
661,813
856,908

electroCore to Participate in Three Upcoming Virtual Investor Conferences

4:01 pm ET July 9, 2020 (Globe Newswire) Print

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive Officer, will participate in three upcoming investor conferences:

Maxim Group/M-Vest COVID-19 Virtual Conference Series: Re-Engaging Medical Practices in an Era of COVID-19

Format: panel discussion

Date: Thursday, July 16

Panel 2, "Can't Touch This! - Time for These Devices to Shine!"

Time: 12:30pm - 1:45pm ET

To access the panel discussion, please RSVP HERE

Zooming with LD Micro

Format: corporate presentation followed by 1x1 virtual investor meetings

Date: Tuesday, July 21

Time: 8:00am - 8:40am PT

Investors can register for the presentation HERE.

Canaccord Genuity 40th Annual Growth Conference

Format: 1x1 virtual investor meetings

Date: Tuesday, August 11

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company's initial targets are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCore

gammaCore (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua), Bronchoconstriction and Medication Overuse Headache in adults.

-- Safety and efficacy of gammaCore have not been evaluated in the following patients:

â?? Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)

â?? Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)

â?? Pediatric patients

â?? Pregnant women

â?? Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

-- Patients should not use gammaCore if they:

â?? Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device

â?? Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck

â?? Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Investors:

Hans Vitzthum

LifeSci Advisors

617-430-7578

hans@lifesciadvisors.com

or

Media Contact:

Jackie Dorsky

electroCore

973-290-0097

jackie.dorsky@electrocore.com

https://ml.globenewswire.com/media/b640fa3f-4363-43d9-a795-4a4279b4fd6c/small/ec-logo-2018-tm-rgb-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.